Chronic kidney disease: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
mNo edit summary
imported>Robert Badgett
Line 17: Line 17:


==Treatment==
==Treatment==
Various drugs have been studied for slowing the progression of chronic kidney disease.<ref name="pmid17943769">{{cite journal |author=Robertson L, Waugh N, Robertson A |title=Protein restriction for diabetic renal disease |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD002181 |year=2007 |pmid=17943769 |doi=10.1002/14651858.CD002181.pub2 |url=http://dx.doi.org/10.1002/14651858.CD002181.pub2 |issn=}}</ref><ref name="pmid16625550">{{cite journal |author=Fouque D, Laville M, Boissel JP |title=Low protein diets for chronic kidney disease in non diabetic adults |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD001892 |year=2006 |pmid=16625550 |doi=10.1002/14651858.CD001892.pub2 |url=http://dx.doi.org/10.1002/14651858.CD001892.pub2 |issn=}}</ref><ref name="pmid17054288">{{cite journal |author=Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC |title=Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD006257 |year=2006 |pmid=17054288 |doi=10.1002/14651858.CD006257 |url=http://dx.doi.org/10.1002/14651858.CD006257 |issn=}}</ref>
{| class="wikitable"
|+ Systematic reviews by the Cochrane Collaboration on treatments for chronic kidney disease
! Treatment !! Setting !!  Results
|-
| Protein restriction<ref name="pmid17943769"/> || Diabetic renal disease || [[relative risk ratio|relative risk]] of end stage renal disease or death:<br/><center>0.23</center>
|-
| Protein restriction<ref name="pmid16625550"/> || Non-diabetic renal disease || [[relative risk ratio|relative risk]] of renal death:<br/><center>0.69</center>
|-
| Angiotensin converting enzyme inhibitors<ref name="pmid17054288"/> || Diabetic renal disease ||&nbsp;
|}
===Medications===
===Medications===
====Angiotensin inhibition====
====Angiotensin inhibition====
Line 23: Line 36:
====Phosphate binders====
====Phosphate binders====
Phosphate binders (calcium carbonate 650 mg tabs three times per day by mouth and calcitriol 0.25-0.5 µg once per day) are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]].
Phosphate binders (calcium carbonate 650 mg tabs three times per day by mouth and calcitriol 0.25-0.5 µg once per day) are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]].
====Allopurinol====
A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a [[relative risk ratio]] of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."<ref name="pmid16377385">{{cite journal |author=Siu YP, Leung KT, Tong MK, Kwan TH |title=Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level |journal=Am. J. Kidney Dis. |volume=47 |issue=1 |pages=51–9 |year=2006 |month=January |pmid=16377385 |doi=10.1053/j.ajkd.2005.10.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(05)01518-0 |issn=}}</ref>


===Renal replacement therapy===
===Renal replacement therapy===

Revision as of 08:50, 16 January 2009

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In medicine, chronic kidney disease is defined as "kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for 3 months or more, irrespective of cause. Kidney damage in many kidney diseases can be ascertained by the presence of albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens."[1]

Classification

There are five stages:[1]

Etiology/cause

Bilateral renal artery stenosis (RAS) may cause 5% to 15% of cases of chronic kidney disease.[2]

Signs and symptoms

Uremia, "the illness accompanying kidney failure", may have subtle manifestations when the glomerular filtration rate falls below 60 ml/min/1.73 m2 [3]

Treatment

Various drugs have been studied for slowing the progression of chronic kidney disease.[4][5][6]

Systematic reviews by the Cochrane Collaboration on treatments for chronic kidney disease
Treatment Setting Results
Protein restriction[4] Diabetic renal disease relative risk of end stage renal disease or death:
0.23
Protein restriction[5] Non-diabetic renal disease relative risk of renal death:
0.69
Angiotensin converting enzyme inhibitors[6] Diabetic renal disease  

Medications

Angiotensin inhibition

Angiotensin can be inhibited with either angiotensin converting enzyme inhibitors[7] or angiotensin II receptor antagonists. These medications can help patients with an elevated creatinine,[8] including those with a creatinine of 1.5 to 5.0 mg per deciliter.[9]

Phosphate binders

Phosphate binders (calcium carbonate 650 mg tabs three times per day by mouth and calcitriol 0.25-0.5 µg once per day) are given once a patient has Stage 3 disease in order to prevent secondary hyperparathyroidism.

Allopurinol

A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a relative risk ratio of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."[10]

Renal replacement therapy

For more information, see: Renal replacement therapy.


References

  1. 1.0 1.1 Levey AS, Eckardt KU, Tsukamoto Y, et al (2005). "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)". Kidney Int. 67 (6): 2089–100. DOI:10.1111/j.1523-1755.2005.00365.x. PMID 15882252. Research Blogging.
  2. Rimmer JM, Gennari FJ (May 1993). "Atherosclerotic renovascular disease and progressive renal failure". Ann. Intern. Med. 118 (9): 712–9. PMID 8460859[e]
  3. Meyer TW, Hostetter TH (2007). "Uremia". N. Engl. J. Med. 357 (13): 1316–25. DOI:10.1056/NEJMra071313. PMID 17898101. Research Blogging.
  4. 4.0 4.1 Robertson L, Waugh N, Robertson A (2007). "Protein restriction for diabetic renal disease". Cochrane Database Syst Rev (4): CD002181. DOI:10.1002/14651858.CD002181.pub2. PMID 17943769. Research Blogging.
  5. 5.0 5.1 Fouque D, Laville M, Boissel JP (2006). "Low protein diets for chronic kidney disease in non diabetic adults". Cochrane Database Syst Rev (2): CD001892. DOI:10.1002/14651858.CD001892.pub2. PMID 16625550. Research Blogging.
  6. 6.0 6.1 Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006). "Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease". Cochrane Database Syst Rev (4): CD006257. DOI:10.1002/14651858.CD006257. PMID 17054288. Research Blogging.
  7. Jafar TH, Stark PC, Schmid CH, et al (2003). "Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis". Ann. Intern. Med. 139 (4): 244–52. PMID 12965979[e]
  8. Ruggenenti P, Perna A, Remuzzi G (2001). "ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy". J. Am. Soc. Nephrol. 12 (12): 2832–7. PMID 11729254[e]
  9. Hou FF, Zhang X, Zhang GH, et al (2006). "Efficacy and safety of benazepril for advanced chronic renal insufficiency". N. Engl. J. Med. 354 (2): 131–40. DOI:10.1056/NEJMoa053107. PMID 16407508. Research Blogging.
  10. Siu YP, Leung KT, Tong MK, Kwan TH (January 2006). "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level". Am. J. Kidney Dis. 47 (1): 51–9. DOI:10.1053/j.ajkd.2005.10.006. PMID 16377385. Research Blogging.

External links